Randomized trial long-term results confirm the benefits of neoadjuvant chemoradiotherapy plus surgery for esophageal cancer
20 May, 2021 | 08:16h | UTC
Commentaries on Twitter
Out at @ASCO_pubs
?yr Outcome of Neoadj #Chemoradiotherapy➕Surgery for #EsophagealCancer☑️Show OS benefit in locally advanced resectable esophageal or junctional #Cancer who receive preop chemorad?☢️ According to CROSS, persists at least?years‼️https://t.co/yJSibSveAh pic.twitter.com/UssnzuFiEe
— Gil Morgan (@weoncologists) May 14, 2021
Survival benefit of preoperative chemoradiotherapy for patients with esophageal cancer persists – 10-year outcome of the CROSS trial https://t.co/s02sMVpYhI #esocsm #JCO @ErasmusMC @bmeyck pic.twitter.com/2JwV0iOvoB
— ASCO Publications (@ASCO_pubs) May 5, 2021